Libivirumab
Monoclonal antibody
NY (what is this?) (verify) Libivirumab is a human monoclonal antibody directed against the hepatitis B virus.[1][2]
References
- ^ WHO Drug Information
- ^ Shouval D, Terrault N, Galun E, Samuel D, Gane E, Pruett T, et al. (2006). "Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatitis B Virus (Hbv) in Liver Transplant (Lt) Recipients". Hepatology. 44 (4): 188A–700A [196A]. doi:10.1002/hep.21395.
- v
- t
- e
Monoclonal antibodies for infectious disease and toxins
Human |
|
---|
Human |
|
---|---|
Chimeric | |
Humanized |
Human | |
---|---|
Mouse | |
Chimeric | |
Humanized |
Human | |
---|---|
Chimeric | |
Humanized |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e